Akorn Inc has received FDA approval to market Paremyd (hydroxyamphetamine hydrobromide 1% & tropicide 0.25%), a topical mydriatic/cycloplegic combination product that Akorn acquired from Allergan Inc in 1997. Akorn expects to launch Paremyd, which will be manufactured in its Somerset, New Jersey facility, in March 2002.
Paremyd is indicated for pupil dilation in routine ophthalmic diagnostic procedures and eye exams. Akorn is the exclusive manufacturer of this unique combination eye drop. Its formulation consists of two well-established ingredients and has demonstrated efficacy superior to either of the active ingredients administered separately. Paremyd's fast onset will benefit patients by decreasing waiting time during their eye exams, thus allowing eye care professionals to better manage patient flow through their office. In addition to its fast onset, Paremyd provides short lasting pupil dilation, sparing patients the often-required dilation reversal step.
Tony Pera, Akorn's president and chief operating officer stated, "We are extremely pleased about the launch of Paremyd, and we believe it represents the first step in re-establishing Akorn's position in the ophthalmic market. Despite the delay in introducing Paremyd, which was attributable to raw material issues and the site transfer process, we are confident that its proven efficacy and treatment benefits will greatly improve patient outcomes."